GSK Spins Out Pain Assets Into Convergence
This article was originally published in Start Up
Executive SummaryThe first spin-out company to result from GlaxoSmith-Kline PLC’s exit from key CNS areas including pain and depression was announced on October 4. UK-based Convergence Pharmaceuticals Ltd. raised $35.4 million (£22.4 million) in one of Europe’s largest Series A rounds.
You may also be interested in...
At its latest R&D review, GSK has culled three of its biotech-like discovery performance units and created four new ones. But less important than the numbers is the new culture, claims CEO Andrew Witty